The report says Aurobindo's EBITDA grew 28% YoY, ahead of estimates, with FY27 guidance retained, and revises TP to INR1,950 maintaining ADD.
Read this note →Aurobindo Pharma Limited
NSE AUROPHARMA BSE 524804 INE406A01037
0 filings · 0 analysed
1,855.30
+9.59%
over 1 month
-
HSIE Results Daily 06 Nov 26 HSIE
The report says Aurobindo's EBITDA grew 28% YoY, ahead of estimates, with FY27 guidance retained, and revises TP to INR1,950 maintaining ADD.
-
The report issues a technical SELL call on Aurobindo Pharma with stoploss 1715 and targets of 1600 and 1575.
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing. Solid markers sit on the exchange's own timestamp.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| HDFC Securities | 06 Nov 2026, 06:42 | long | 1,800.00 | 1,950.00 | — | — | open by 2027-11-06 |
| Sharekhan (Mirae Asset Sharekhan) | 14 Oct 2026, 16:23 | short | 1,662.90 | 1,575.00 | 1,571.70 | 104% | hit |
| Sharekhan Limited (Mirae Asset Sharekhan) | 08 Oct 2026, 16:40 | short | 1,645.00 | 1.00 | 1,800.00 | -9% | open by 2027-10-08 |
| HDFC Securities | 07 Oct 2026, 15:25 | long | 1,682.00 | 1,730.00 | 1,785.00 | 200% | hit |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report issues a technical SELL call on Aurobindo Pharma with stoploss 1715 and targets of 1600 and 1575.
Read this note →The note lists Aurobindo Pharma as a 1-5 day technical SELL at a CMP of Rs 1,645 with a stoploss of 1,700.
Read this note →The report expects 18% YoY revenue growth driven by Lannett integration and Europe momentum, calling it among the strong performers this quarter.
Read this note →The report notes Aurobindo underwent two USFDA inspections in September 2026 resulting in Form 483 observations, and forecasts sales growth of 16.1% YoY.
Read this note →The report notes Aurobindo Pharma's subsidiary Acrotech Biopharma launched ADQUEY ointment in the US, marking its entry into US dermatology market, viewed positively.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief